ICE PROTOKOLÜ

Kaynaklar:

1- Hertzberg, M. S., C. Crombie, et al. (2003). "Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease." Ann.Oncol. 14 Suppl 1:i11-6.: i11-i16.

2- Vose, J. and V. Sneller (2003). "Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma." Ann.Oncol. 14 Suppl 1:i17-20.: i17-i20.

3-Moskowitz, C. H., S. D. Nimer, A. D. Zelenetz, et al. 2001. "A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model." Blood 97(3):616-623.

4-Hertzberg, M. S., C. Crombie, W. Benson, et al. 2006. "Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma." Ann Oncol 17 Suppl 4:iv25-30.

5-Moskowitz, C. H., J. R. Bertino, J. R. Glassman, et al. 1999. "Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma." J Clin Oncol 17(12):3776-3785.